Shots:

• The study A of P-III LIBERTY CUPID trial evaluates Dupixent vs SoC in 138 patients aged ≥6 yrs. with CSU who remained symptomatic despite antihistamine use and who were not previously treated with anti-IgE therapeutics
• The trial met its 1EPs & 2EPs @24wks. i.e. showed a reduction in itch severity (63% vs 35%)- reduction in urticaria activity (itch and hives) severity (65% vs 37%) while safety results were like the known safety profile of Dupixent
• The ongoing Study B evaluates Dupixent in adults & adolescents who remain symptomatic despite SOC treatment and are intolerant or incomplete responders to omalizumab with its expected results in H1’22. The companies plan to start regulatory submissions in 2022

Ref: Regeneron| Image: Clinical Trials Arena